Australia markets open in 44 minutes

ALK-Abelló A/S (0OIR.IL)

IOB - IOB Delayed price. Currency in DKK
Add to watchlist
127.75-21.70 (-14.52%)
At close: 05:58PM GMT
Full screen
Previous close149.45
Open128.50
Bid0.00 x 0
Ask0.00 x 0
Day's range126.80 - 129.39
52-week range70.40 - 132.40
Volume23,535
Avg. volume58,732
Market cap25.645B
Beta (5Y monthly)0.31
PE ratio (TTM)79.35
EPS (TTM)1.61
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date16 Mar 2017
1y target estN/A
  • GlobeNewswire

    Annual General Meeting in ALK-Abelló A/S on 14 March 2024

    ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK

  • GlobeNewswire

    Annual report 2023: ALK delivers 9% sales growth with profits up 50%

    08 February 2024 ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK expects to continue its growth trajectory and earnings improvement in 2024. (Revenue and earnings growth rates are stated in local currencies. Comparative figures for 2022 are shown in brackets.) Q4 2023 financial highlights Revenue increased by 10% to DKK 1,345 million (1,249) wit

  • GlobeNewswire

    ALK and McMaster researchers discover new cell that remembers allergies

    Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abelló A/S have made a ground-breaking discovery: a new cell that remembers allergies. The discovery gives scientists and researchers a new target in treating allergies and could lead to new therapeutics. The research, published in Science Translational Medicine on Feb. 7, 2024, coins the brand-new cell as a type-2 memory B cell (MBC2). “We’ve discovered a type of memory B cell that had unique characteristics and a